Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;65(3):354-364.
doi: 10.1007/s12016-023-08972-2. Epub 2023 Nov 2.

A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data

Felix Johnson  1 , Anna Stenzl  2 , Benedikt Hofauer  1 , Helen Heppt  1 , Eva-Vanessa Ebert  3 , Barbara Wollenberg  3 , Robin Lochbaum  4 , Janina Hahn  4 , Jens Greve  4 , Susanne Trainotti  3
Affiliations
Review

A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data

Felix Johnson et al. Clin Rev Allergy Immunol. 2023 Dec.

Abstract

Hereditary angioedema (HAE) and acquired C1-inhibitor deficiency (AAE-C1-INH) are orphan diseases. Berotralstat is a recently licensed long-term prophylaxis (LTP) and the first oral therapy for HAE patients. No approved therapies exist for AAE-C1-INH patients. This study is the first to report real-world clinical data of patients with AAE-C1-INH and HAE who received Berotralstat. All patients treated with Berotralstat were included in this retrospective, bi-centric study. Data was collected from patients' attack calendars and the angioedema quality of life (AE-QoL) and angioedema control test (AECT) questionnaires before treatment, and at 3, 6, and 12 months after treatment and was then analyzed. Twelve patients were included, 3 patients with AAE-C1-INH, 7 patients with HAE type I, and 2 patients with HAE-nC1-INH. One patient (HAE I) quit treatment. Berotralstat was associated with fewer attacks in all groups. After 6 months of treatment, a median decrease of attacks per month was noted for HAE type I patients (3.3 to 1.5) and AAE-C1-INH patients (2.3 to 1.0). No aerodigestive attacks were noted for AAE-C1-INH patients. For HAE-nC1-INH patients, a mean decrease from 3.8 to 1.0 was noted (3 months). For HAE I patients, the total AE-QoL lowered a mean of 24.1 points after 6 months, for HAE-nC1-HAE patients 8.0 points, and for AAE-C1-INH patients 13.7 points. AECT scores increased for HAE I patients (mean: 7.1), HAE-nC1-INH patients (9.0), and AAE-C1-INH patients (4.2) after 6 months. Patients with HAE, HAE-nC1-INH, and AAE-C1-INH treated with Berotralstat showed reduced angioedema attacks and improved AE-QoL and AECT scores.

Keywords: AAE-C1-INH; Acquired angioedema; Berotralstat; Bradykinin; C1-INH-deficiency; HAE; Hereditary angioedema; LTP; Long-term prophylaxis; Prophylaxis.

PubMed Disclaimer

Conflict of interest statement

No financial assistance from any pharmaceutical company was obtained for this study. The authors of this study declare the following conflict of interests: F. Johnson: has received grant research support and/or speaker/consultancy fees from CSL Behring, Takeda and Pharming. He has also received funding to attend conferences/educational events from CSL Behring, Takeda and Pharming. He has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, IONIS Pharmaceuticals and Takeda. A. Stenzl: has no conflict of interest to declare regarding this publication B. Hofauer: has participated as an investigator in clinical trials for CSL Behring and Takeda. H. Heppt: has no conflict of interest to declare regarding this publication E. Ebert: has received grant research support and/or speaker/consultancy fees from CSL Behring and Takeda. She has also received funding to attend conferences/educational events from CSL Behring, Takeda and Pharming. She has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, IONIS Pharmaceuticals and Takeda. J. Hahn: has received speaker/consultancy fees from CSL Behring and Takeda. She has also received funding to attend conferences/educational events from CSL Behring and Takeda. She has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, Pharvaris and Takeda. J. Greve: has received speaker/consultancy fees from CSL Behring, Takeda, Kalvista and BioCryst. He has also received funding to attend conferences/educational events from CSL Behring and Takeda. He has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst and Takeda. B. Wollenberg: has no conflict of interest to declare regarding this publication R. Lochbaum: Robin Lochbaum has received consultancy fees from BioCryst and Takeda. He has also received funding to attend conferences/educational events from CSL Behring, BioCryst and Takeda. He has participated as an investigator in a clinical trial/registry for Takeda and Pharvaris. S. Trainotti: has received grant research support and/or speaker/consultancy fees from CSL Behring and Takeda. She has also received funding to attend conferences/educational events from CSL Behring and Takeda. She has participated as an investigator in a clinical trial/registry for CSL Behring, BioCryst, IONIS Pharmaceuticals and Takeda.

Figures

Fig. 1
Fig. 1
Total attacks before and after LTP with Berotralstat for AAE-C1-INH patients (n = 3)
Fig. 2
Fig. 2
Monthly attack rate before and after LTP with Berotralstat for AAE-C1-INH patients (n = 3)
Fig. 3
Fig. 3
Attack rate per domain before and after LTP with Berotralstat for AAE-C1-INH patients (n = 3)
Fig. 4
Fig. 4
Total AE-QoL for all the patients AAE-C1-INH and HAE (n = 12) over the whole observation period
Fig. 5
Fig. 5
Analysis of AE-QoL scores pre-dose and after 6 months using Wilcoxon matched pairs test signed rank test (p < 0.0449)
Fig. 6
Fig. 6
Total AECT for all the patients AAE-C1-INH and HAE (n = 12) over the whole observation period
Fig. 7
Fig. 7
Analysis of AECT scores pre-dose and after 6 months using Wilcoxon matched pairs test signed rank test (p < 0.0289)
See this image and copyright information in PMC

References

    1. Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13:73. doi: 10.1186/s13023-018-0815-5. - DOI - PMC - PubMed
    1. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2010;6:14. doi: 10.1186/1710-1492-6-14. - DOI - PMC - PubMed
    1. Kivity S. New perspectives in acquired angioedema. Isr Med Assoc J IMAJ. 2014;16:313–314. - PubMed
    1. Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O, Fabien V, Andresen I. Comparing acquired angioedema with hereditary angioedema (types i/ii): findings from the Icatibant Outcome Survey. Clin Exp Immunol. 2017;188:148–153. doi: 10.1111/cei.12910. - DOI - PMC - PubMed
    1. Zanichelli A, Azin GM, Wu MA, Suffritti C, Maggioni L, Caccia S, Perego F, Vacchini R, Cicardi M. Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2017;5:1307–1313. doi: 10.1016/j.jaip.2016.12.032. - DOI - PubMed

MeSH terms

LinkOut - more resources